HCPCS code J1439 – Ferric carboxymaltose injection

Key takeaways

J1439 covers ferric carboxymaltose (Injectafer) injection and is billed per 1 mg administered, so a 750 mg dose equals 750 billable units.

Units are capped per labeled dose: 750 mg for adult IDA, and up to 1,000 mg for NDD-CKD or heart failure.

Medicare Part B pays J1439 at ASP+6% in the physician office, while a hospital outpatient department bills the drug on the UB-04 under OPPS.

Many Medicaid programs and commercial plans want the 11-digit NDC with qualifier N4 beside J1439, and a missing NDC is a frequent denial trigger.

Pabau, the practice management platform we build, validates each J1439 claim before submission and tracks it from Pending to Paid.

HCPCS code J1439: Definition and quick-reference facts

HCPCS code J1439 is a J-code in the HCPCS Level II code set, which the Centers for Medicare and Medicaid Services maintains. It identifies the drug ferric carboxymaltose, and its official descriptor is “Injection, ferric carboxymaltose, 1 mg.” Each unit represents 1 mg administered, not the vial size purchased. Physician offices report it on a CMS-1500 or 837P claim, and hospitals report it on the UB-04.

Ferric carboxymaltose: Clinical overview for coders

Ferric carboxymaltose (FCM) is an intravenous iron replacement. Its FDA label covers three patient groups, and coders need to know them because claims for off-label use are denied on medical-necessity grounds. Check these criteria at the point of scheduling, before the infusion is booked.

• Iron deficiency anemia (IDA) in adults and pediatric patients aged 1 and older who can’t tolerate oral iron or don’t respond to it
• IDA in adults with non-dialysis-dependent chronic kidney disease (NDD-CKD)
• Iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure

The drug is given intravenously, and the labeled dose depends on the indication and the patient’s weight. For adult IDA in patients weighing 50 kg or more, each dose is 750 mg. Two doses go at least seven days apart, for a course total of 1,500 mg.

Adults with NDD-CKD who weigh 50 kg or more may receive a single 1,000 mg dose instead. Heart failure doses run from 500 mg to 1,000 mg. Children receive 15 mg/kg per dose, capped at 750 mg. The unit ceiling is therefore set per labeled dose for the indication, and billing more units than that invites a payer audit.

How to calculate J1439 units: Worked examples

J1439 unit math is simple: Bill one unit for every milligram administered. The common errors are billing the vial size instead of the dose given, or billing a whole course’s milligrams on one claim date.

Partial vials: Bill the milligrams administered on one line. Medicare takes any discarded amount from a single-dose vial on a separate line with the JW modifier. When nothing is discarded, it requires the JZ modifier instead.

Because the labeled dose changes with the indication, so does the most a single J1439 line should carry, as the chart below shows.

Covered diagnoses: ICD-10 codes that support J1439 claims

Every J1439 claim needs an ICD-10-CM diagnosis code that matches an FDA-approved indication. An unrelated or insufficiently specific diagnosis is a frequent denial reason for this drug code.

Important: Dialysis-dependent CKD is not an FDA-approved indication for Injectafer, so those claims are denied. Write “non-dialysis-dependent” explicitly in the physician order when billing for CKD patients.

Place of service: Where J1439 can be billed

The place of service (POS) code decides which Medicare payment system applies to J1439, so it must match where the infusion happens. A physician-office POS on an infusion given in a hospital outpatient department is a compliance risk and an audit trigger.

Medicaid POS rules are state-specific. North Carolina Medicaid, for example, publishes J1439 billing guidelines that specify approved settings. Verify each state program’s current policy before submitting.

Administration CPT codes to pair with J1439

HCPCS code J1439 covers the drug only. Giving the infusion is a separate service, usually coded with 96365 for the first hour. Billing J1439 without an administration code underpays the practice or triggers a payer edit.

• CPT 96365: Intravenous infusion, drug/substance, initial, up to one hour. This is the primary administration code for an FCM infusion. Bill it once per infusion encounter, even when several drugs run in sequence.
• CPT 96366: Each additional hour of infusion beyond the first. An FCM infusion usually finishes within the first hour, so 96365 alone typically covers it.
• CPT 96367: Additional sequential infusion of a new drug or substance. Use it only when a different drug runs after the FCM infusion in the same encounter.

Bundling caution: CPT 96365 and J1439 are complementary codes, and both must appear on the claim. Some payers apply a National Correct Coding Initiative (NCCI) edit when infusion and injection administration codes are billed for the same drug. Confirm the edit status with your MAC before adding more administration codes.

J1439 Medicare reimbursement: Rates and how to look them up

Medicare Part B pays for J1439 in the physician office using the Average Sales Price plus six percent (ASP+6%) methodology. CMS calculates the ASP each quarter from manufacturer-reported sales data, with updates in January, April, July and October. Because rates change every quarter, cite any per-unit dollar figure with its quarter and year.

To find the current rate, download the latest quarterly file from the CMS ASP pricing files and search for J1439. The file lists the per-unit payment limit, which is multiplied by the units billed.

Medicaid reimbursement is set by each state. Some states pay close to Medicare’s ASP+6%, while others use a state fee schedule or a managed Medicaid plan rate. Never apply one state’s published rate to another state’s claims.

J1439 prior authorization requirements by payer type

Prior authorization (PA) for J1439 is not universal, but many commercial plans and Medicaid programs require it, so check the payer policy. A denied claim on a 750 mg Injectafer dose is a substantial write-off. Confirm insurance eligibility verification and PA requirements before scheduling the infusion, not after.

• Traditional Medicare Part B: Generally does not require PA for Part B drugs, J1439 included. However, a Medicare Administrative Contractor (MAC) may publish a Local Coverage Determination (LCD) whose criteria call for documented clinical justification. Check your MAC’s LCD before assuming no PA is needed.
• Medicare Advantage plans: May require PA even when traditional Medicare does not. Treat each plan like a commercial payer for PA purposes.
• Commercial plans: Many require PA, so check each payer’s policy. Criteria typically include a documented IDA diagnosis and lab values confirming iron deficiency (ferritin, TSAT, hemoglobin). Plans also ask for documented failure or intolerance of at least one oral iron product.
• Medicaid: Many state Medicaid and managed Medicaid plans require PA for Injectafer, so check the state policy. Required documentation and approval turnaround vary by state.

NDC reporting requirements for J1439

Most state Medicaid programs require the 11-digit National Drug Code (NDC) on the claim line alongside HCPCS code J1439. Many commercial plans now require it as well. A missing or incorrect NDC is a frequent denial reason on J1439 claims sent to Medicaid.

The NDC for Injectafer can change with packaging updates. Take it from the label of the vial used for the infusion, never from a stored record of an earlier purchase. Confirm current Injectafer NDC numbers with your pharmacy or wholesaler.

J1439 vs. other iron infusion codes: Choosing the right one

A frequent miscoding error is reporting J1756, the iron sucrose (Venofer) code, for a ferric carboxymaltose infusion. Another is reporting J3490 (unclassified drug) when a specific code exists. Each iron infusion drug has its own HCPCS code, and the wrong one is an upcoding or downcoding risk, depending on relative payment rates.

J3490 should never be used when J1439 applies. Reporting an unclassified code for a drug with a specific HCPCS code is an audit risk. It typically triggers a manual pricing review that delays payment.

Common J1439 claim denial reasons and how to fix them

J1439 denials cluster around six predictable errors, and a pre-submission checklist catches most of them. Strong denial management processes stop these before the claim leaves the practice.

Step-by-step J1439 claim submission

A complete J1439 claim follows a consistent checklist, and each step below maps to a field or documentation element on the 837P transaction. Treating submission as a clean claim workflow reduces denials before they occur.

1. Confirm the FDA-approved indication. Verify the chart supports a labeled indication. That means IDA with documented oral iron failure or intolerance, IDA with NDD-CKD, or iron deficiency with NYHA class II/III heart failure. Record the clinical rationale in the physician order.
2. Obtain prior authorization from the payer if required. Record the PA number, because it goes on the claim.
3. Record the lot number and NDC from the drug vial at the time of administration. Add both to the infusion nursing note.
4. Calculate units. Milligrams administered equal units billed, with no rounding up. Units on one date of service never exceed the labeled dose for the indication.
5. Select the POS code that matches the infusion location, such as POS 11 for the office or POS 22 for hospital outpatient.
6. Pair with CPT 96365 for the first infusion hour. Add CPT 96366 only if the infusion runs past one hour.
7. Attach supporting ICD-10 codes (D50.x, N18.x with D63.1, or E61.1 with the heart failure code, as applicable).
8. Submit the NDC on the 837P claim line with qualifier N4, the 11-digit code, the quantity and the unit of measure.
9. Review the remittance advice. If the claim is denied, identify the CARC/RARC reason codes and appeal with supporting documentation.

Documentation requirements for J1439 claims

Incomplete documentation is a frequent audit finding on J1439 claims. A payer or Recovery Audit Contractor (RAC) expects a superbill documentation trail that reconstructs the clinical decision, the drug administered and the dose given.

• Physician order specifying drug, dose, route, frequency and clinical indication
• Infusion nursing note with start and stop times, drug name, lot number, NDC, dose administered and patient response
• Drug label or vial record confirming the NDC and lot number used
• Diagnosis documentation linking the visit to iron deficiency anemia, CKD-related anemia or iron deficiency in heart failure
• Lab results confirming iron deficiency at or near the time of treatment (hemoglobin, ferritin, TSAT)
• Oral iron trial record documenting intolerance or inadequate response (for the IDA indication)
• Prior authorization approval letter or reference number when PA was required

How Pabau keeps J1439 claim lines clean

Many infusion practices still build a J1439 claim by hand from the nursing note, the drug invoice and the payer’s PA letter. Each copy step is a chance to drop the NDC, mistype the units or lose the authorization number.

Pabau’s error-catching claims management opens each claim pre-filled from the patient’s invoice. Claim validation flags missing or invalid details before you submit, and prior authorization codes follow the appointment onto the claim. Claims go out as CMS-1500s through Claim.MD, and you can check eligibility before the visit.

Once a claim is out, the dashboard tracks it from Pending to Paid. Payments settle straight from electronic remittance advice (ERA) files, so you can spot a short-paid drug line without matching payments by hand.

Submit cleaner infusion drug claims

Pabau validates each J1439 claim before submission, carries the prior authorization code onto it and tracks payment from Pending to Paid. See how it fits your infusion practice.

Book a demo

Conclusion

Treat 750 units as one labeled dose, not a universal limit. When the units on the claim match the indication in the chart, a 1,000-unit heart failure or NDD-CKD line has the documentation to back it.

The NDC and the prior authorization number are easy to lose between the infusion chair and the billing desk. Capture both at the chair, and the claim leaves complete.

The trade-off is a few extra minutes of nursing documentation per infusion, set against a write-off on a high-cost drug. Book a demo to see how Pabau validates J1439 claims before they reach the clearinghouse.

Continue your research

Need to understand how claims move through the clearinghouse? Medical claims clearinghouse explained covers how 837P files are validated and routed to payers before payment.

Getting denials you can’t decode? Denial codes in medical billing breaks down CARC and RARC reason codes and the corrective actions that go with each.

Need to check what the payer paid on each drug line? Electronic remittance advice explains how 835 ERA files confirm payment and flag underpayments on drug claims.

Billing ferumoxytol instead? HCPCS code Q0138 covers Feraheme for patients who are not on dialysis.

Infusing iron dextran? HCPCS code J1750 explains INFeD billing, which counts units in 50 mg steps rather than 1 mg.

Frequently asked questions